Clinical trials: Gene Mutations
Non-small-lung-cell Cancer, NSCLC
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients
This study is a randomized, multicenter clinical study ，which is designed to compare the efficacy of the safety and efficacy of treatment every 6 weeks in EGFR positive (Non-small cell lung cancer, NSCLC) with concurrent Driver…
- Conditions
- Non-small-lung-cell Cancer, NSCLC, EGFR Gene Mutation
- Trial name
- NCT04552613
- Testing
- EGFR-TKI, EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)
- Where
- China
- Volunteers
- 114 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Oligoasthenozoospermia, Male Infertility
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men
Infertility remains a significant global burden. Estimates suggest that 10-15% of couples worldwide experience infertility, with male infertility being the underlying cause in 20-50% of cases.
- Trial name
- NCT07402759
- Testing
- L-carnitine
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- South Valley University
Her-2 Negative Breast Cancer, HRR Gene Mutation
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with…
- Trial name
- IMPARP (NCT05761470)
- Testing
- Camrelizumab, Fluzoparib, Nab-paclitaxel
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ying Lin
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study
The goal of this observational study is to examine whether markers of PI3K pathway activation are associated with endocrine therapy response and clinicopathologic features in estrogen receptor-positive, HER2-negative breast…
- Trial name
- p-AKT p-S6 (NCT07387861)
- Testing
- Not applicable- observational study
- Volunteers
- 70 people
- Sponsor
- Assiut University
Amyotrophic Lateral Sclerosis
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
The ALSpire Study is a clinical trial evaluating the investigational drug BIIB105 in adults living with amyotrophic lateral sclerosis (ALS). The ALSpire Study consists of two parts: Part 1: 6-month placebo-controlled study.
- Trial name
- ALSpire (NCT04494256)
- Testing
- BIIB105
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 99 people
- Sponsor
- Biogen
Acute Myeloid Leukemia (AML)
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
The researchers are doing this study to see if the combination of gilteritinib with ivosidenib or enasidenib is a safe and effective treatment for people with relapsed/refractory AML with FLT3/IDH1 or FLT3/IDH2 gene mutations.
- Trial name
- NCT05756777
- Testing
- Gilteritinib, Ivosidenib, Enasidenib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Susceptibility, Genetic, Chemotherapy Effect
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
We plan to carry out a prospective, randomized, open phase III clinical trial which sponsored by the Tianjin Medical University Cancer Hospital and Institute.
- Trial name
- NCT03359694
- Testing
- DT group, ET group, NX group
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis.
- Conditions
- BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation
- Trial name
- NCT04009148
- Testing
- CASCADE genetic screening
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Lung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
To evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy for limited metastatic NSCLC harboring sensitizing EGFR mutations after first line TKI therapy.
- Trial name
- NCT02788058
- Testing
- EGFR-TKI, Thoracic Hypofractionated Radiotherapy
- Volunteers
- 76 people
- Sponsor
- First People's Hospital of Hangzhou
Drug Monitoring, Carcinoma, Non-Small-Cell Lung
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
The ADAPT ALEC randomized controlled trial (RCT) is performed in patients with Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC).
- Conditions
- Drug Monitoring, Carcinoma, Non-Small-Cell Lung, Lung Cancer, Anaplastic Lymphoma Kinase Gene Mutation
- Trial name
- ADAPT ALEC (NCT05525338)
- Testing
- Alectinib
- Where
- 8 sites in France, Netherlands
- Volunteers
- 196 people
- Sponsor
- University Medical Center Groningen
Glioma, Recurrence
Vorasidenib Expanded Access Program
This is an expanded access program to provide vorasidenib for treatment of patients 12 years or older with IDH1- or IDH2-mutated glioma.
- Conditions
- Glioma, Recurrence, Disease Attributes, Pathologic Processes
- Trial name
- NCT05592743
- Testing
- Vorasidenib
- Sponsor
- Servier
Non Small Cell Lung Cancer
Resistance to Oral Therapy in Lung Cancer
In the management of non-small cell lung cancer of the adenocarcinoma type, different therapeutic strategies can be proposed. These strategies are defined according to the results of a biological analysis of blood and/or tissue…
- Trial name
- RESTKI (NCT04546282)
- Testing
- Description of the molecular alterations detected in blood samples of patients treated by osimertinib
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Montpellier
Hemoglobin Mutations, Erythrocyte Variants
Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research
This study will collect blood samples for use in laboratory studies of malaria. The World Health Organization reports that 40 percent of the world's population is at risk for malaria, mostly in the poorest countries.
- Trial name
- NCT00277849
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
This randomized, open-label study will evaluate the safety and efficacy of Avastin (Bevacizumab) added to standard mFOLFOX6 chemotherapy in treatment-naïve patients with Stage IV metastatic colorectal cancer.
- Trial name
- NCT01338558
- Testing
- bevacizumab [Avastin], cetuximab, mFOLFOX6
- Sponsor
- Hoffmann-La Roche
Mutation, Obesity
Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16
Chinese male subjects will be invited to participate in a research study of brown fat, a special tissue in the body that is designed to burn energy to make heat.
- Conditions
- Mutation, Obesity, Dyslipidemia, Diabetes
- Trial name
- NCT02808715
- Testing
- Blood Sample Collection
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- National Heart Centre Singapore
Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
This phase II trial studies how well enasidenib works in treating in patients with acute myeloid leukemia with an IDH2 gene mutation that has come back or has not responded to treatment.
- Conditions
- Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT03881735
- Testing
- Enasidenib, Hematopoietic Cell Transplantation
- Where
- 2 sites in United States
- Sponsor
- Roswell Park Cancer Institute
Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
This phase I/II trial tests the safety, side effects, best dose and how well giving daraxonrasib works for the treatment of pediatric patients with solid tumors with RAS mutations that has come back after a period of improvement…
- Conditions
- Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma, Recurrent Childhood Rhabdomyosarcoma, Refractory Childhood Malignant Solid Neoplasm
- Trial name
- NCT07819838
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Volunteers
- 77 people
- Sponsor
- Children's Oncology Group
Erythromelalgia
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations
This research study is designed to investigate brain response using fMRI scan, and behavioral responses, to treatment with the drug carbamazepine (CBZ) in patients with the painful sodium channelopathy inherited Erythromelalgia…
- Trial name
- NCT02214615
- Testing
- Carbamazepine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- VA Connecticut Healthcare System
Hirschsprung Disease
Genetic Mosaicism in Hirschsprung's Disease
Hirschsprung's disease is a complex genetic disorder. The etiology of this disease is not completely understood. It is characterized by the absence of ganglia (nerve cells) in de distal colon.
- Trial name
- NCT01927809
- Where
- 2 sites in Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
HIV Infection
TMC125-C223: TMC125 in HIV-1 Infected Subjects
The purpose of this study is to investigate the ability of TMC125, a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), to lower the amount of virus in your blood when administered twice daily for 48 weeks.
- Trial name
- NCT00081978
- Testing
- TMC125
- Volunteers
- 211 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.